Examining the association between oncology drug clinical benefit and the time to public reimbursement

BACKGROUND: We examined if oncology drug indications with high clinical benefit, as measured by the American Society of Clinical Oncology Value Framework (ASCO‐VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO‐MCBS), received public reimbursement status faster t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomson, Sasha, Everest, Louis, Witzke, Noah, Jiao, Tina, Delos Santos, Seanthel, Nguyen, Vivian, Cheung, Matthew C., Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729052/
https://www.ncbi.nlm.nih.gov/pubmed/34850587
http://dx.doi.org/10.1002/cam4.4455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729052/
https://www.ncbi.nlm.nih.gov/pubmed/34850587
http://dx.doi.org/10.1002/cam4.4455

Ejemplares similares